Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
The Current Status of Breast Cancer Among Resource-Limited Countries
1
4
41926
EN
Shahla
Masood
Department of Pathology, University of Florida, College of Medicine Jacksonville,
Jacksonville, Florida,USA
Journal Article
2013
10
02
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Esophageal Cancer in Iran: A Review
5
14
41925
EN
Alireza
Sadjadi
Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical
Sciences, Tehran, Iran
Hajiamin
Marjani
Gastroenterology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Shahryar
Semnani
Gastroenterology Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Siavosh
Nasseri-Moghaddam
Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical
Sciences, Tehran, Iran
Journal Article
2013
10
02
Esophageal cancer is the second and third most common malignancy in Iranian males and females, respectively, claiming lives of approximately 5800 Iranians each year. Squamous cell carcinoma (SCC) is presently the most common type accounting for about 90% of all esophageal cancers in Iran. Recent studies have shown that there is a gradual increase in the incidence of adenocarcinoma of the distal esophagus along with gastric cardia adenocarcinoma. Thirty-five years ago, the age standardizied rate (ASR) of esophageal SCC in the city of Gonbad (Golestan Province, northeast of Iran) was found to be one of the highest rates for any single cancer that had been reported worldwide (ASR >100/105/year). Recent studies have shown that the incidence of SCC in Gonbad has declined to less than half of what it was in the past. This decline in the incidence of esophageal SCC parallels an improvement in the socioeconomic situation of people living in this region. According to recent cancer registry data in Iran there is still an obvious intracountry variability between the incidence of esophageal cancer in the south with an ASR of 3 for males and 2 for females in Kerman and 43 and 36 in the northeastern province of Golestan. The reasons for this very high rate of SCC in northeastern Iran have been the subject of several studies during the past 35 years. According to results of these studies the suspected risk factors are: low intake of fruits and vegetables, drinking hot tea, consumption of opium products and tobacco, H.pylori infection in the stomach, using unhealthy drinking water from cisterns and genetic susceptibility. The main suspected mutagens are polycyclic aromatic hydrocarbons (PAH) and N-nitroso compounds. In order to embark primary and secondary prevention of this fatal cancer, further prospective studies are presently underway in the region. The Golestan esophageal cancer cohort study which follows of 50,000 subjects is on going. We expect simple and feasible evidence based preventive strategies to be implemented in the future according to the results of this study.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
CTLA-4 Exon One +49A/G Gene Variants in Patients with Superficial and Invasive Bladder Cancer: A Study in Southern Iran
15
20
41924
EN
Alireza
Aminsharifi
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
Abbas
Ghaderi
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
0000-0003-0849-3375
Sirous
Naeimi
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
Abdolaziz
Khezri
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
Neda
Agahi
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
Amir
Aminian
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
Nima
Zamiri
Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Journal Article
2013
10
02
Introduction: Cytotoxic T-cell lymphocyte antigen 4 (CTLA-4) is a member of the superfamily of immunoglobulins that are mainly expressed by activated T cells. It is established that blockade of CTLA-4 receptors leads to the enhancement of an immune response. Different polymorphisms of the CTLA-4 gene have been described which cause increased susceptibility to various malignancies such as lymphoma or multiple myeloma. Considering that bladder cancer is one of the most prevalent cancers worldwide, we have evaluated the role of CTLA-4 gene polymorphism at position +49 A/G in the formation or progression of bladder cancer in southern Iran.Materials and Methods:Atotal of 226 individuals between February 2005 and June 2006 were included and placed into two subgroups: patients diagnosed with bladder cancer and a control group. Demographic data and risk factors were collected from both groups. The DNAof all subjects was extracted from their blood samples. Different genotypes of the CTLA-4 gene were determined using the restriction fragment length polymorphism (RFLP) technique and data were compared in both groups by using Pearson's chi-square test.Results: The prevalence of AA, AG and GG genotypes at position 49, according to the PCR-RFLP method, were 57.5%, 37.2% and 5.3% in the control group, respectively. In the patient group, the prevalence of these genotypes was: AAin 57.5%, AG in 32.7% and GG in 9.8%. Statistical analysis of data showed no significant difference in both groups (P value=0.40). Also there was no correlation between different genotypes of the CTLA-4 gene and invasiveness of the disease in our cases.Conclusion: Although polymorphism of the CTLA-4 gene at position 49 of exon-1 increases susceptibility to several malignancies, our study showed no relationship between polymorphism at this position and genetic susceptibility to the development of bladder cancer, nor was there any association with disease progression.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
High Concentration of Serum Soluble Fas in Patients with Head and Neck Carcinoma: A Comparative Study Before and After Surgical Removal of Tumor
21
26
41927
EN
Mojtaba
Habibagahi
Immunotherapy Laboratory, Department of Immunology, Shiraz University of Medical
Sciences, Shiraz,Iran
Mansooreh
Jaberipour
Cancer Gene Therapy Laboratory, Shiraz Institute for Cancer Research, Shiraz University
of Medical Sciences, Shiraz,Iran
Mohammad Javad
Fattahi
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz,Iran
Seyed Basir
Hashemi
Department of Ear, Nose and Throat, Khalili Hospital, Shiraz University of Medical
Sciences, Shiraz,Iran
Mahmood
Shariati
Department of Immunology, Shiraz University of Medical Sciences, Shiraz,Iran
Journal Article
2013
10
02
Background: Alternative splicing of the Fas transcript can produce a natural secreted isoform of this molecule. Some cancer cells can also produce soluble Fas (sFas) which may have suppressive effects on the immune system's anti-tumor response. Elevated concentrations of sFas have been detected in the sera of patients with different malignancies.Materials and Methods: The concentrations of sFas in sera of patients with head and neck carcinoma (HNC, n=98) and healthy individuals (n=30) were measured by Sandwich ELISAand compared to values obtained six months after surgical removal of the tumor (n=48). Data were correlated with different clinical findings of the patients.Results: sFas concentrations in the sera of HNC patients were found to be significantly higher in patients with different tumor stages. sFas concentration did not correlate with age or tumor invasiveness, however a higher concentration of sFas was found in the sera of patients who had higher tumor grades. Surgical removal of tumors in patients resulted in a substantial decrease in sFas concentration.Conclusion: The initial rise in sFas concentration in the sera of HNC patients and its consequent decrease could be regarded as a sign of tumor suppressive mechanisms. Additional studies are needed to fully elucidate this mechanism however these findings might show the prospective use of such biomarkers to determine disease prognosis and even immunotherapeutic applications.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Differences in Molecular Pathologic Characteristics of Pancreatic Adenocarcinoma between Egyptian and Moroccan Patients
27
36
41929
EN
Sara
Robinson
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor,
Michigan, USA
Amr S.
Soliman
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor,
Michigan, USA
Mehdi
Karkouri
Department of Pathology, Mohammed V University, Casablanca, Morocco
Hoda Gad
Omer
Department of Pathology, Tanta Cancer Center, Tanta, Egypt
Joel F.
Greenson
Department of Pathology, University of Michigan School of Medicine, Ann Arbor,
Michigan, USA
Journal Article
2013
10
02
Introduction: Pancreatic cancer has not been well studied, especially in developing countries.Materials and Methods: We studied the variations in genetic mutations in pancreatic adenocarcinoma between Moroccan and Egyptian populations. The molecular pathology of 30 tumors from a large hospital in Casablanca, Morocco were examined and compared with the findings of 44 tumors from the Gharbiah Governate in Egypt. K-ras mutations in codons12 and 13 in addition to p53 mutations in exons 5-8 were evaluated.Results: Overall, differences in the rates of K-ras mutations were not statistically significant (48.00 and 34.09%, respectively); however differences in rates of p53 mutations were statistically significant with p53 mutations more common in Moroccan tumors than in Egyptian tumors (46.67 and 16.28%, respectively). Gļ¢Tmutations of the K-ras gene were most commonly seen Egyptian tumors, whereas Gļ¢Amutations were the most common type of mutations in Moroccan tumors. Logistic regression analysis showed that a p53 mutation in any exon as well as a p53 mutation in exon 5 predicted the country of residence and those mutations occurred more frequently in Moroccan patients. Conclusion: Our study shows that differences exist within the Arab population in the molecular pathology of both the K-ras and p53 genes. Further studies are necessary to clarify the differences in molecular pathways of pancreatic cancer in the Middle East and to investigate the role of environmental and/or genetic factors related to those pathways.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Are Patients with Malignancy More Prone to Swine Flu Complications? Current Status and Future Strategic Plans
37
39
41922
EN
Behnam
Sabayan
Health Policy Research Center, School of Medicine, Shiraz University of Medical
Sciences, Shiraz, Iran
Kamran
Bagheri Lankarani
Health Policy Research Center, School of Medicine, Shiraz University of Medical
Sciences, Shiraz, Iran
Azadeh
Vaghefikia
Health Policy Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Journal Article
2013
10
02
N/A
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Cancer Epidemiology in Lebanon
41
44
41921
EN
Ali I.
Shamseddine
Department of Internal Medicine, Hematology & Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
0000-0003-3725-8403
Khaled M.
Musallam
Department of Internal Medicine, Hematology & Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
Journal Article
2013
10
02
The main obstacle facing cancer preventive strategies worldwide is a lack of well conducted epidemiological studies to guide local and international efforts for disease control. In Lebanon, long due political strain has added yet another obstacle to the development of methodologies aiming to collect data on cancer epidemiology. However, through several efforts dated from the 1960s the picture is becoming clearer. We herein review the outcome of all such efforts and their interpretation as a guide for future preventive strategies.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Cervical Lymph Node Metastases from Meningioma: Report of Two Cases and Treatment Outcome
45
49
41920
EN
Shapour
Omidvari
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0003-3656-9891
Hamid
Nasrolahi
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
Yahya
Daneshbod
Dr. Daneshbod Pathology Lab, Shiraz, Iran
Neda
Bagheri
Dr. Daneshbod Pathology Lab, Shiraz, Iran
Shahrzad
Negahban
Dr. Daneshbod Pathology Lab, Shiraz, Iran
Mohammad
Mohammadianpanah
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0001-9391-8977
Niloofar
Ahmadloo
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0003-3178-8577
Mansour
Ansari
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0002-8249-1776
Ahmad
Mosalaei
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran
0000-0002-3986-8865
Journal Article
2013
10
02
Meningioma is usually a benign central nervous system (CNS) tumor. Metastasis is rare; however if it does occur the most metastatic sites are the liver and lungs. Here, two cases of CNS meningioma with metastasis to cervical lymph nodes are reported. The first case, a 48 year-old man developed cervical lymph node metastasis nine years after primary tumor diagnosis. The second case, a 23 year-old woman with parietal lobe meningioma, developed lymph node metastasis in the neck nine months after the diagnosis of meningioma.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Lipoma Arborescens of the Knee: Report of a Case with Full Range of Motion
51
54
41928
EN
Ahmad
Ensafdaran
Research Center for Bone and Joint Diseases, Department of Orthopedics,
Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Amir Reza
Vosoughi
Research Center for Bone and Joint Diseases, Department of Orthopedics, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Arash
Khozai
Research Center for Bone and Joint Diseases, Department of Orthopedics, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Simin
Torabi
Department of Pathology and Shiraz Nephrology Urology Research Center,
Shiraz University of Medical Sciences, Shiraz, Iran
Mohammad Reza
Ensafdaran
Research Center for Bone and Joint Diseases, Department of Orthopedics, Chamran Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Journal Article
2013
10
02
This report describes a rare intra-articular benign tumor, lipoma arborescens, of the knee joint in a 21 year-old female. The patient suffered from left knee joint swelling for five years with occasional pain. Swelling was soft and boggy in the suprapatellar area. Motion of joint was complete. No abnormality was detected in any laboratory tests. MRI showed a large soft tissue density in the suprapatellar area with high signal intensity on T1 and T2 weighted images. Operative arthroscopy revealed a creamy brown hypertrophied synovium with diffuse papillary processes characterized by villous proliferation of the synovium infiltrated by mature fat tissue, chronic inflammatory cells and vessels as seen in the pathologic slides. Lipoma arborescens or villous lipomatous proliferation of the synovial membrane should be distinguished from other similar lipomatoid conditions such as synovial lipoma and Hoffa disease. Lipoma arborescens should be considered in patients with painless, slowly progressive swelling of a joint, especially the knee.
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Squamous Cell Carcinoma of the Head and Neck: Dramatic Response to Chemoradiotherapy
55
57
41919
EN
Ahmad
Mosalaei
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
0000-0002-3986-8865
Seyed Basir
Hashemi
Department of Ear, Nose and Throat, Khalili Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
Sanaz
Sedaghat
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
Journal Article
2013
10
02
N/A
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
1
1
2010
01
01
Middle East Journal of Cancer: A Regional Initiative
41923
EN
Farhad
Handjani
Middle East Journal of Cancer, Shiraz University of Medical sciences, Shiraz, Iran
Journal Article
2013
10
02